Aston Particle Technologies is the developer of a novel technology, iDPC, a tuneable blending process which greatly simplifies formulating active pharmaceutical ingredients in the drug production process. iDPC enhances the properties of drug formulations and provides a simpler route to developing high-dose dry powder inhalers, oral solid-dose drugs, fixed-dose combination drugs, and biologics. The technology allows pharmaceutical companies to develop the undevelopable and manufacture the unmanufacturable.

Aston Particle Technologies spun out of Aston University in 2016 following its development in Professor Afzal Mohammed’s Pharmaceutical & Clinical Pharmacy Research Group, with the support of Chairman and co-founder, Ian Smith, an industry expert in inhalation product development. David Wyatt since joined the company as CEO, bringing over 35 years’ experience in respiratory medicine across development to commercialisation.

DSW Ventures made a £716,000 EIS qualifying investment in April 2022 as part of a £1.016m raise alongside co-investors Aston University and an Aston alumnus. This funding will support in-house development of a lead anti-fungal compound, scale-up of manufacturing capabilities and its commercialisation through product and business development hires.